Pluri Inc. (PLUR) 股票分析

公司概述

Pluri Inc. is a biotechnology enterprise dedicated to the research, development, and manufacture of cell-based products, cell therapeutics, and associated technologies tailored for diverse industrial applications. The company specifically focuses on advancing placenta-based cell therapy product candidates designed to treat conditions such as inflammatory disorders, muscle injuries, and other related ailments. Operating within the Healthcare sector and the Biotechnology industry, Pluri functions in a specialized environment where high-risk scientific innovation drives potential market disruption. The company's current scale is defined by a market capitalization of $32.56 million, annual revenue of $1.34 million, and an employee base of 127 individuals. These financial metrics indicate that Pluri operates as a small-cap entity with limited revenue generation relative to its market valuation, suggesting a company in an early-stage or growth-oriented phase where valuation is often driven by pipeline potential rather than established cash flows or profitability.

财务健康

Pluri Inc. reported revenue of $1.34 million over the trailing twelve months, yet it incurred a net income loss of $26.138 million, revealing a significant discrepancy where operational costs and R&D expenses vastly outweighed gross revenue. The company's EBITDA stood at a loss of $24.435 million, further illustrating that the burn rate is substantial and that the business model has not yet achieved operational breakeven. Free cash flow was negative at $14.34875 million, indicating that the company is consuming cash reserves to fund its operations and development efforts rather than generating liquidity. The gross margin stands at 40.6%, which suggests that the cost of goods sold is relatively contained compared to total sales, though this is insufficient to cover overhead. Conversely, the operating margin is reported at -3285.9%, a figure that highlights severe inefficiencies or extraordinary non-operating expenses eroding the bottom line before interest and taxes. The profit margin is 0.0%, confirming that the company has not generated any net income to date. On the balance sheet, Pluri holds $12.48 million in cash against $34.94 million in debt, creating a net debt position that signals a leveraged financial structure reliant on financing. The debt-to-equity ratio is listed as N/A, which typically occurs when equity is negative due to accumulated losses, masking the true leverage picture. The current ratio is 0.43, indicating that current assets are less than half of current liabilities, which points to potential short-term liquidity challenges in meeting immediate obligations. Return on Equity is N/A due to the negative equity base, while the return on assets is -50.6%, demonstrating that management is currently destroying value relative to the assets employed rather than generating a positive return.

估值评估

The P/E ratio (TTM) is N/A due to the lack of earnings, while the forward P/E is listed as -1.71, a metric that is mathematically derived from negative earnings expectations and offers limited traditional valuation insight. The price-to-book ratio is -2.21, indicating that the market price is significantly below the book value, a common characteristic for biotech firms with negative shareholder equity that market participants may view as a distressed or deep-value opportunity. The price-to-sales ratio is 24.32, suggesting that investors are valuing the company at 24 times its annual revenue, which implies a high premium placed on future growth prospects despite current unprofitability. The EV/EBITDA stands at -2.47, further reinforcing that traditional enterprise value metrics are skewed by the company's negative earnings and cash generation. Pluri's stock has traded between a 52-week high of $7.13 and a 52-week low of $2.82, and without the current specific share price provided in the facts, the exact percentage distance from the high cannot be calculated, but the range demonstrates significant volatility within a trading band of $4.31. The beta value is 0.73, indicating that the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market swings compared to the average large-cap stock.

Growth & Income

Pluri Inc. has achieved a revenue growth rate of 7.0% year-over-year, whereas earnings growth is listed as N/A because the company is currently unprofitable. The absence of positive earnings growth relative to revenue growth implies that the company is still in a phase of heavy investment where top-line expansion has not yet translated to bottom-line profitability. Regarding income distribution, the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This lack of a dividend payout signifies that the company retains all its limited earnings—or rather, its cash reserves—to reinvest into research, development, and operational scaling rather than distributing returns to shareholders. The overall growth and income profile for Pluri Inc. is characterized by modest single-digit revenue expansion paired with a complete absence of current income generation, requiring the company to rely entirely on external capital markets or internal cash reserves to sustain operations.